Freitag, 10. September | 23:43 Uhr

DJ euro adhoc: Sartorius AG / quarterly or semiannual financial statement / Figures for the First Quarter of 2008Sales revenue rose 3.8% (currency-adjusted: up 7.7%) | Currency-adjusted order intake up 3.4% | EBITA at EUR12.2 million up from the previous year | EBITA margin unchanged at 8.2%

Sartorius AG / quarterly or semiannual financial statement 

=-------------------------------------------------------------------------------
  Disclosure announcement transmitted by euro adhoc. The issuer is responsible
  for the content of this announcement.
=------------------------------------------------------------------------------- 

22.04.2008 

To ensure the best possible comparability, the first-quarter figures of 2007
are shown on a pro forma basis and adjusted for extraordinary expenses. 

Within the first three months of 2008, the Sartorius Group increased sales
revenue by 3.8% to EUR149.2 million (Q1 2007: EUR143.6 mn). Currency-adjusted
consolidated sales revenue climbed 7.7%. The Biotechnology Division's sales
revenue rose 5.4% (currency-adjusted: +9.5%) to EUR90.6 (Q1 2007: EUR85.9 mn).
Sales revenue for the Mechatronics Division grew 1.5% (currency-adjusted:
+5.1%) to EUR58.6 million (Q1 2007: EUR57.7 mn). 

At EUR162.5 million, order intake was higher than sales revenue and thus at the
high level of the year-earlier quarter (EUR162.9 mn). On the basis of constant
currencies, order intake rose 3.4%. The difference between sales revenue and
order intake essentially resulted from the fluctuations in the equipment
business of the Biotechnology Division. The Division's order intake was EUR97.6
million (Q1 2007: EUR99.1 million), which corresponds to a decline of 1.5% or a
currency-adjusted increase of 2.2%. The value of orders for the Mechatronics
Division rose 1.8% or by a currency-adjusted rate of 5.3%. 

First-quarter operating earnings (earnings before interest, taxes and
amortization = EBITA) increased from EUR11.8 million to EUR12.2 million. At
8.2%, the EBITA margin remained unchanged compared to the year-earlier figure.
If the EBITA margin had been calculated based on the previous year's exchange
rates, it would have increased to more than 9%. EBITA for the Biotechnology
Division rose from EUR8.4 million to EUR9.1; for the Mechatronics Division,
EBITA at EUR3.1 million was below the year-earlier figure of EUR3.4 million. Net
profit after minority interest was EUR3.2 million (Q1 2007: EUR3.5 million);
earnings per share (excluding the two non-cash items of amortization and
interest on share price warrants granted) were EUR0.25 (Q1 2007: EUR0.26). 

For the full fiscal year of 2008, the Sartorius Group is continuing to aim at
achieving sales revenue growth of more than 9% in constant currencies. Based on
this anticipated sales revenue and on an average exchange rate of 1.40 USD/EUR,
the Group is planning to increase the EBITA margin to approx. 12%. 

|EUR in millions                |Q1 2008 |Q1 2007   |Change     |
|(unless otherwise specified)   |        |pro forma |in %       |
|                               |        |          |           |
|Sartorius Group                |        |          |           |
|Sales revenue                  |149.2   |143.6     |+3.8 (+7.7)|
|Order intake                   |162.5   |162.9     |-0.2 (+3.4)|
|EBITA 1)                       |12.2    |11.8      |+3.7       |
|Net profit for the period 1)2) |4.2     |4.4       |-2.9       |
|Earnings per share 1)2) in EUR |0.25    |0.26      |-2.9       |
|                               |        |          |           |
|Biotechnology Division         |        |          |           |
|Sales revenue                  |90.6    |85.9      |+5.4 (+9.5)|
|Order intake                   |97.6    |99.1      |-1.5 (+2.2)|
|EBITA 1)                       |9.1     |8.4       |+8.5       |
|                               |        |          |           |
|Mechatronics Division          |        |          |           |
|Sales revenue                  |58.6    |57.7      |+1.5 (+5.1)|
|Order intake                   |64.9    |63.8      |+1.8 (+5.3)|
|EBITA 1)                       |3.1     |3.4       |-7.9       | 

in parentheses: currency-adjusted
1) for 2007 underlying
2) excluding non-cash amortization and, for 2008, additionally excluding
non-cash interest expenses for share price warrants 

Dr. Joachim Kreuzburg, CEO of Sartorius, will discuss the quarterly results for
Sartorius with analysts and investors in a teleconference at 4:30 p.m. CET
following today's Annual Shareholder Meeting. You may dial into this
teleconference starting at 4:15 p.m. CET at the following numbers: 

Germany: +49 (0)69 5007 1316;
France: +33 (0)1 70 99 42 99;
UK: +44 (0)20 7806 1968;
USA: +1 718 354 1387. 

The dial-in code is 3601455; 

to view the webcast, log onto
www.livemeeting.com/cc/premconfeurope/join?id=3601455&role=attend&pw=pw7076 

=---------------------- 

end of announcement                               euro adhoc
=------------------------------------------------------------------------------- 

(END) Dow Jones Newswires

April 22, 2008 15:21 ET (19:21 GMT)